In8Bio Inc (INAB) Stock Price, Quote & News

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 600 6438

Website: in8bio.com

Address:

350 5th Avenue, Suite 5330, New York, United States

TWITLIEDETECTOR Nov. 17 at 5:25 AM

$INAB interesting place this companies in. above $1 but running on fumes with good up

0 · Reply

BigTimePennyStocks Nov. 17 at 12:45 AM

Small-Caps with Catalysts this week: 👇👇 ( $ATOS, $AEON, $INAB, $AIRE, $RVYL, etc...) #NASDAQ #NYSE

1 · Reply

ZekeBalderdash Nov. 12 at 4:37 PM

$INAB Digging in a little more, it seems very unlikely to me that the GBM data will be a turning point. The update would have to show significantly better results than the early data to de-risk the investment enough for big pharma in the current environment. Good enough to merit continuation, almost certainly, but not enough to make a partnership likely. The AML data stand a real chance of being transformative, but will they publish before running out of money? Will they find some funding that isn't horrifically dilutive to get them there? They're on a knife edge.

0 · Reply

Space_Jam23 Nov. 10 at 9:19 AM

$INAB Keep watching on this.. it might run $10

1 · Reply

Brooklyn_Queens Nov. 10 at 12:06 AM

$INAB Any day now...

1 · Reply

Ag035 Nov. 8 at 2:31 AM

$INAB have fun with this MALO clown. report his account. dude is a troll.

0 · Reply

AndreaRR Nov. 8 at 12:32 AM

$INAB

0 · Reply

WallStreetIsNotEasy Nov. 7 at 4:19 PM

$INAB Get ready for below $1 it’s coming

0 · Reply

d_risk Nov. 7 at 4:12 AM

$INAB - IN8BIO, INC. - 10Q - Updated Risk Factors INAB’s latest 10-Q risk factors spotlight urgent going concern doubts, critical capital needs, manufacturing and supply chain hurdles, reliance on key partners and personnel, expanded IP and litigation threats, clinical and regulatory uncertainties, commercialization and reimbursement challenges, volatile stock risks, and heightened exposure to financial, compliance, and operational disruptions. #Biotechnology #IntellectualProperty #RegulatoryUncertainty #SupplyChain #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/INAB/10-Q/2025-11-06

0 · Reply